Jingwei Sun
Research Subjects
Jingwei Sun has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Jun Wang
Department of Pathology, New York University Grossman School of Medicine, New York, USA
10 shared publications - Ala. F. Nassar
Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA
9 shared publications - Dejian Zhao
Yale Center for Genome Analysis, Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA
9 shared publications - Edward Quinlan
Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
9 shared publications - Franz Villarroel-Espíndola
Translational Medicine Laboratory, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
9 shared publications - Kurt A. Schalper
Department of Pathology, Yale School of Medicine, New Haven, USA
9 shared publications
Latest Publications
- Open Access
- 24 February 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (2) , 48
Discover personalized drug opportunity and optimized tumor-infiltrating lymphocyte therapy for rare cancer: an organoid-based whole-journey clinical mapping study in a neuroendocrine cancer patient
Purpose Rare cancer patients face dire prognoses due to high malignancy and scarce treatment options, underscoring an imperative for personalized strategies. This study aims to evaluate the potential of precision medicine to extend survival in rare cancer patients by leveraging personalized tumor organoids (PTOs) as a discovery platform to comprehensively explore and generate new treatment opportunities. Methods We performed whole-journey clinical mapping in a neuroendocrine cervical cancer (NECC) patient with chemo-resistant metastases. Longitudinal PTOs from three recurrent lesions and autologous tumor-infiltrating lymphocytes (TILs) were established to correlate clinical responses and discover new therapies. A co-culture system integrating PTOs and autologous TILs was developed to replicate clinical responses and optimize TIL therapy through rebuilding tumor antigen microenvironment. Results PTOs recapitulated tumor evolution and resistance imprints, enabling identification of a highly effective targeted therapy candidate post-chemotherapy failure. The co-culture system faithfully mirrored clinical immunotherapy responses, validating its potential as a companion diagnostic. Utilizing PTOs to rebuild the autologous tumor antigen microenvironment during TIL production generated a personalized, optimized TIL population. These optimized TILs exhibited enhanced anti-tumor ability and their administration correlated with clinical tumor regression in the patient. Generalizability of this PTO-based optimization strategy was validated across both patients and cancer types. Conclusion This study establishes that survival for rare cancer patients hinges on integrated, personalized companion diagnostics and therapy optimization. By bridging iterative tumor models with clinical interventions, we provide a scalable conceptual framework to overcome therapeutic nihilism and unlock precision-driven survival benefits.
- 24 February 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (2) , 48
Open AccessDiscover personalized drug opportunity and optimized tumor-infiltrating lymphocyte therapy for rare cancer: an organoid-based whole-journey clinical mapping study in a neuroendocrine cancer patient
Purpose Rare cancer patients face dire prognoses due to high malignancy and scarce treatment options, underscoring an imperative for personalized strategies. This study aims to evaluate the potential of precision medicine to extend survival in rare cancer patients by leveraging personalized tumor organoids (PTOs) as a discovery platform to comprehensively explore and generate new treatment opportunities. Methods We performed whole-journey clinical mapping in a neuroendocrine cervical cancer (NECC) patient with chemo-resistant metastases. Longitudinal PTOs from three recurrent lesions and autologous tumor-infiltrating lymphocytes (TILs) were established to correlate clinical responses and discover new therapies. A co-culture system integrating PTOs and autologous TILs was developed to replicate clinical responses and optimize TIL therapy through rebuilding tumor antigen microenvironment. Results PTOs recapitulated tumor evolution and resistance imprints, enabling identification of a highly effective targeted therapy candidate post-chemotherapy failure. The co-culture system faithfully mirrored clinical immunotherapy responses, validating its potential as a companion diagnostic. Utilizing PTOs to rebuild the autologous tumor antigen microenvironment during TIL production generated a personalized, optimized TIL population. These optimized TILs exhibited enhanced anti-tumor ability and their administration correlated with clinical tumor regression in the patient. Generalizability of this PTO-based optimization strategy was validated across both patients and cancer types. Conclusion This study establishes that survival for rare cancer patients hinges on integrated, personalized companion diagnostics and therapy optimization. By bridging iterative tumor models with clinical interventions, we provide a scalable conceptual framework to overcome therapeutic nihilism and unlock precision-driven survival benefits.
- 13 September 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (12) , 6101-6117
High-fidelity AaCas12bMax enables the development of an engineered T cell therapy with enhanced safety and functional fitness
- 13 September 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (12) , 6101-6117
High-fidelity AaCas12bMax enables the development of an engineered T cell therapy with enhanced safety and functional fitness
- Open Access
- 11 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (37) , e06827
Engineering DNA Origami Captors for TGFβ1 Sequestration to Enhance Tumor Immune Modulation and Therapy
Efficient modulation of pivotal immune‐regulatory molecules to leverage the tumor microenvironment (TME) and enhance therapeutic effects remains an ideal yet challenging goal. TGFβ1 represents a critical therapeutic target as a key cytokine involved in immune suppression and tumor progression. Here, a DNA origami‐based framework functionalized with anti‐TGFβ1 aptamers is developed to act as a captor for efficient TGFβ1 sequestration and fast clearance, thereby improving anti‐tumor immunity. By engineering the geometric shapes and pore sizes of three DNA framework captors (DFCs), the superior efficacy of a barrel‐shaped captor (DBC) in regulating TGFβ1 levels is demonstrated. In cell culture, DBCs significantly enhance T cell‐mediated tumor cytotoxicity, while systemic administration effectively inhibits tumor growth in the mouse model. Moreover, DBCs demonstrate a synergistic effect with PD‐L1 antibody to enhance anti‐tumor efficacy. Immunohistochemistry (IHC) further confirmes the DBC‐mediated reduction of TGFβ in tumor tissue and its biodistribution fate. These findings underscore the importance of cytokine regulation in cancer immunotherapy and provide valuable insights for the rational design and application of structural DNA nano‐devices as a transformative tool for precise immunomodulation.
- 11 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (37) , e06827
Open AccessEngineering DNA Origami Captors for TGFβ1 Sequestration to Enhance Tumor Immune Modulation and Therapy
Efficient modulation of pivotal immune‐regulatory molecules to leverage the tumor microenvironment (TME) and enhance therapeutic effects remains an ideal yet challenging goal. TGFβ1 represents a critical therapeutic target as a key cytokine involved in immune suppression and tumor progression. Here, a DNA origami‐based framework functionalized with anti‐TGFβ1 aptamers is developed to act as a captor for efficient TGFβ1 sequestration and fast clearance, thereby improving anti‐tumor immunity. By engineering the geometric shapes and pore sizes of three DNA framework captors (DFCs), the superior efficacy of a barrel‐shaped captor (DBC) in regulating TGFβ1 levels is demonstrated. In cell culture, DBCs significantly enhance T cell‐mediated tumor cytotoxicity, while systemic administration effectively inhibits tumor growth in the mouse model. Moreover, DBCs demonstrate a synergistic effect with PD‐L1 antibody to enhance anti‐tumor efficacy. Immunohistochemistry (IHC) further confirmes the DBC‐mediated reduction of TGFβ in tumor tissue and its biodistribution fate. These findings underscore the importance of cytokine regulation in cancer immunotherapy and provide valuable insights for the rational design and application of structural DNA nano‐devices as a transformative tool for precise immunomodulation.
- Open Access
- 14 July 2023
- Published by Springer Nature in British Journal of Cancer
- Vol. 129 (7) , 1041-1049
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer
Tumour immunotherapy has achieved remarkable clinical success in many different types of cancer in the past two decades. The outcome of immune checkpoint inhibitors in cancer patients has been linked to the quality and magnitude of T cell, NK cell, and more recently, B cell within the tumour microenvironment, suggesting that the immune landscape of a tumour is highly connected to patient response and prognosis. It is critical to understanding tumour immune microenvironments for identifying immune modifiers of cancer progression and developing cancer immunotherapies. The infiltration of solid tumours by immune cells with anti-tumour activity is both a strong prognostic factor and a therapeutic goal. Recent approaches and applications of new technologies, especially single-cell mRNA analysis in dissecting tumour microenvironments have brought important insights into the biology of tumour-infiltrating immune cells, revealed a remarkable degree of cellular heterogeneity and distinct patterns of immune response. In this review, we will discuss recent advances in the understanding of tumour infiltrated lymphocytes, their prognostic benefit, and predictive value for immunotherapy.
- 14 July 2023
- Published by Springer Nature in British Journal of Cancer
- Vol. 129 (7) , 1041-1049
Open AccessThe prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer
Tumour immunotherapy has achieved remarkable clinical success in many different types of cancer in the past two decades. The outcome of immune checkpoint inhibitors in cancer patients has been linked to the quality and magnitude of T cell, NK cell, and more recently, B cell within the tumour microenvironment, suggesting that the immune landscape of a tumour is highly connected to patient response and prognosis. It is critical to understanding tumour immune microenvironments for identifying immune modifiers of cancer progression and developing cancer immunotherapies. The infiltration of solid tumours by immune cells with anti-tumour activity is both a strong prognostic factor and a therapeutic goal. Recent approaches and applications of new technologies, especially single-cell mRNA analysis in dissecting tumour microenvironments have brought important insights into the biology of tumour-infiltrating immune cells, revealed a remarkable degree of cellular heterogeneity and distinct patterns of immune response. In this review, we will discuss recent advances in the understanding of tumour infiltrated lymphocytes, their prognostic benefit, and predictive value for immunotherapy.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy
Specific mechanisms by which tumor-infiltrating lymphocytes (TIL) become dysfunctional remain poorly understood. Here, we employed a two-pronged approach using single-cell mass cytometry and tissue imaging technologies to dissect TILs from 25 patients with resectable and 35 patients with advanced non–small cell lung cancer (NSCLC). We identified a burned-out CD8+ TIL subset (Ebo) that specifically accumulated within the tumor microenvironment (TME) but not in adjacent nontumoral tissues. Ebo showed the highest expression of proliferation and activation markers but produced the lowest amount of IFNγ and were the most apoptotic CD8+ TIL subset. Using a humanized patient-derived tumor xenograft model, we demonstrated that Ebo expansion occurred within the TME in a PD-1/B7-H1 pathway-dependent manner. Ebo abundance in baseline tumor tissues was associated with resistance to anti-PD therapy in patients with NSCLC. Our study identifies a dysfunctional TIL subset, with distinct features from previously described exhausted T cells, and implies strategies to overcome immunotherapy resistance.Significance:We identified a highly proliferative, overactivated, and apoptotic dysfunctional CD8+ tumor-infiltrating subpopulation that is functionally distinct from previously described exhausted T cells. This population is expanded in lung cancer tissues in a PD-1/B7-H1-dependent manner, and its abundance is associated with resistance to cancer immunotherapy, thus becoming a potential tissue biomarker.This article is highlighted in the In This Issue feature, p. 1601
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy
Specific mechanisms by which tumor-infiltrating lymphocytes (TIL) become dysfunctional remain poorly understood. Here, we employed a two-pronged approach using single-cell mass cytometry and tissue imaging technologies to dissect TILs from 25 patients with resectable and 35 patients with advanced non–small cell lung cancer (NSCLC). We identified a burned-out CD8+ TIL subset (Ebo) that specifically accumulated within the tumor microenvironment (TME) but not in adjacent nontumoral tissues. Ebo showed the highest expression of proliferation and activation markers but produced the lowest amount of IFNγ and were the most apoptotic CD8+ TIL subset. Using a humanized patient-derived tumor xenograft model, we demonstrated that Ebo expansion occurred within the TME in a PD-1/B7-H1 pathway-dependent manner. Ebo abundance in baseline tumor tissues was associated with resistance to anti-PD therapy in patients with NSCLC. Our study identifies a dysfunctional TIL subset, with distinct features from previously described exhausted T cells, and implies strategies to overcome immunotherapy resistance.Significance:We identified a highly proliferative, overactivated, and apoptotic dysfunctional CD8+ tumor-infiltrating subpopulation that is functionally distinct from previously described exhausted T cells. This population is expanded in lung cancer tissues in a PD-1/B7-H1-dependent manner, and its abundance is associated with resistance to cancer immunotherapy, thus becoming a potential tissue biomarker.This article is highlighted in the In This Issue feature, p. 1601